
Publication|Videos|July 31, 2023
Deep Dive into the Use of Real-World Registry Data as External Control Arms
Author(s)CorEvitas
While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.
Advertisement
Watch this video and learn more:
- Challenges faced by biopharma companies conducting clinical trials when studying rare conditions.
- The purpose of a control population in traditional randomized controlled clinical trials.
- How hybrid control arms can improve the strength of control groups.
- How prospective registries serve as real-world control populations.
- How to minimize bias between populations or outcome measures across RCT control groups vs. real-world/hybrid controls.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bob Mauch: Strengthening the Chain
2
Novo Nordisk Stock Reacts to Recent Board Changes
3
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5